Cargando…

Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study

This study was performed to investigate the effects of bitter melon extract (BME) on glucose metabolism, insulin resistance, and various metabolic parameters of participants with prediabetes. A 12-week randomized placebo-controlled clinical study was conducted with prediabetic patients. A total of 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Bukyung, Lee, Hak Sung, Kim, Hye-Jin, Lee, Hyolynn, Lee, In-young, Ock, Soyoung, Kwon, Sukyoung, Kang, Sang-Soo, Choi, Youngsik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050654/
https://www.ncbi.nlm.nih.gov/pubmed/37009042
http://dx.doi.org/10.1007/s10068-022-01214-9
_version_ 1785014681791889408
author Kim, Bukyung
Lee, Hak Sung
Kim, Hye-Jin
Lee, Hyolynn
Lee, In-young
Ock, Soyoung
Kwon, Sukyoung
Kang, Sang-Soo
Choi, Youngsik
author_facet Kim, Bukyung
Lee, Hak Sung
Kim, Hye-Jin
Lee, Hyolynn
Lee, In-young
Ock, Soyoung
Kwon, Sukyoung
Kang, Sang-Soo
Choi, Youngsik
author_sort Kim, Bukyung
collection PubMed
description This study was performed to investigate the effects of bitter melon extract (BME) on glucose metabolism, insulin resistance, and various metabolic parameters of participants with prediabetes. A 12-week randomized placebo-controlled clinical study was conducted with prediabetic patients. A total of 76 participants were randomly assigned to initiate the study. In the final analysis, 33 and 32 subjects were included in the BME and placebo groups, respectively. Results showed that 75 g oral glucose tolerance test (OGTT) blood glucose level decreased in BME group after 12 weeks. The glucose level after 30 min of glucose ingestion decreased significantly. The glucagon level in the BME group after 12 weeks significantly decreased 120 min after 75 g OGTT. These results suggested that bitter melon exhibits glucose-lowering effects through suppression of glucagon levels in people with prediabetes.
format Online
Article
Text
id pubmed-10050654
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-100506542023-03-30 Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study Kim, Bukyung Lee, Hak Sung Kim, Hye-Jin Lee, Hyolynn Lee, In-young Ock, Soyoung Kwon, Sukyoung Kang, Sang-Soo Choi, Youngsik Food Sci Biotechnol Research Article This study was performed to investigate the effects of bitter melon extract (BME) on glucose metabolism, insulin resistance, and various metabolic parameters of participants with prediabetes. A 12-week randomized placebo-controlled clinical study was conducted with prediabetic patients. A total of 76 participants were randomly assigned to initiate the study. In the final analysis, 33 and 32 subjects were included in the BME and placebo groups, respectively. Results showed that 75 g oral glucose tolerance test (OGTT) blood glucose level decreased in BME group after 12 weeks. The glucose level after 30 min of glucose ingestion decreased significantly. The glucagon level in the BME group after 12 weeks significantly decreased 120 min after 75 g OGTT. These results suggested that bitter melon exhibits glucose-lowering effects through suppression of glucagon levels in people with prediabetes. Springer Nature Singapore 2022-12-14 /pmc/articles/PMC10050654/ /pubmed/37009042 http://dx.doi.org/10.1007/s10068-022-01214-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Kim, Bukyung
Lee, Hak Sung
Kim, Hye-Jin
Lee, Hyolynn
Lee, In-young
Ock, Soyoung
Kwon, Sukyoung
Kang, Sang-Soo
Choi, Youngsik
Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title_full Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title_fullStr Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title_full_unstemmed Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title_short Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
title_sort momordica charantia (bitter melon) efficacy and safety on glucose metabolism in korean prediabetes participants: a 12-week, randomized clinical study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050654/
https://www.ncbi.nlm.nih.gov/pubmed/37009042
http://dx.doi.org/10.1007/s10068-022-01214-9
work_keys_str_mv AT kimbukyung momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT leehaksung momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT kimhyejin momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT leehyolynn momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT leeinyoung momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT ocksoyoung momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT kwonsukyoung momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT kangsangsoo momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy
AT choiyoungsik momordicacharantiabittermelonefficacyandsafetyonglucosemetabolisminkoreanprediabetesparticipantsa12weekrandomizedclinicalstudy